Losartan D4, the deuterium-labeled version of Losartan, functions as an angiotensin II receptor antagonist. It inhibits the interaction between angiotensin II and AT1 receptors by competing for binding, achieving an IC50 value of 20 nM.
Dapiglutide (ZP7570) is a long-acting dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon-like peptide-2 receptor (GLP-2R) that holds potential for short bowel syndrome (SBS) research.
GS-9822 is a novel LEDGIN, an inhibitor that targets the binding pocket of LEDGF/p75 which is a cellular cofactor that substantially contributes to HIV integration site selection, displaying a block-and-lock phenotype in cell culture.